Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) Operating Expenses (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Operating Expenses for 2 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 130.55% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Dec 2025, down 26.48% year-over-year, with the annual reading at $17.4 million for FY2025, 5.69% down from the prior year.
  • Operating Expenses for Q4 2025 was $5.6 million at NRX Pharmaceuticals, up from $4.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $7.0 million in Q2 2024, with the low at $2.4 million in Q4 2024.